Press Releases

Home/Press Releases

Oramed to Present at H.C. Wainwright BioConnect 2021 Conference

NEW YORK, Jan. 7, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the H.C. Wainwright BioConnect 2021 [...]

2021-01-07T08:40:00+00:00Categories: Press Releases|Tags: |

Oramed Initiates Phase 2 NASH Trial of Oral Insulin

NEW YORK, Dec. 2, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened the first patients in a global trial of its oral insulin capsule [...]

2020-12-02T08:25:00+00:00Categories: Press Releases|Tags: |

Oramed Initiates Phase 3 Trial of Oral Insulin

NEW YORK, Nov, 24, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened  the first patients in its global Phase 3 trials of its oral insulin capsule ORMD-0801 [...]

2020-11-24T08:10:00+00:00Categories: Press Releases|Tags: |

Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar “Oral Delivery of Therapeutic Proteins – Oramed Story” on November 18, 2020

NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Nobel Laureate Prof. Avram Hershko and Oramed Chief Scientific Officer Dr. Miriam  Kidron will join Premas [...]

2020-11-12T08:40:00+00:00Categories: Press Releases|Tags: |

Oramed to Present Phase 2b Oral Insulin Data at American Association of Pharmaceutical Scientists 2020 PharmSci 360 Conference

NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it is presenting a poster at the 2020 American Association of Pharmaceutical Scientists (AAPS) 2020 [...]

2020-10-28T08:40:00+00:00Categories: Press Releases|Tags: |

Oramed CEO Nadav Kidron & Premas Biotech to Host Webinar “The Journey of Oral Insulin: Oramed Story” on Wednesday October 28, 2020

NEW YORK, Oct. 27, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will join Premas Biotech's Co-Founder and Managing Director Dr. Prabuddha Kundu in [...]

2020-10-27T08:55:00+00:00Categories: Press Releases|Tags: |

Oramed Issues Shareholder Update on Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted to FDA

1,125 patients combined in both studies Efficacy data available after the 6-month dosing NEW YORK, Oct. 16, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the [...]

2020-10-16T08:40:00+00:00Categories: Press Releases|Tags: |

Oramed Pharmaceuticals to Present at the European Association for the Study of Diabetes (EASD) Annual Meeting

Oral Presentation on Oral Insulin Effect on Diabetes and Poster Presentation on Oral Insulin Effect on NASH NEW YORK, Sept. 21, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, [...]

2020-09-21T08:25:00+00:00Categories: Press Releases|Tags: |